Kidney Transplant Recipients Clinical Trial
Official title:
Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.
This is an open label, non-randomized study in kidney transplant recipients who received two doses of either mRNA COVID-19 vaccine and have a negative (<0.8 U/mL) or low (titer <50 U/mL) SARS-CoV-2 antibody response using the Roche Elecsys® anti-RBD assay. Eligible participants will receive a third dose of the same mRNA vaccine as the prior two doses. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01336296 -
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
|
Phase 4 | |
| Recruiting |
NCT01150487 -
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
|
N/A | |
| Recruiting |
NCT05938712 -
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
|
Phase 2 | |
| Completed |
NCT00217100 -
A Multivitamin Comparison Study in Kidney Transplant Recipients.
|
Phase 3 | |
| Active, not recruiting |
NCT00199667 -
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT01517984 -
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
|
Phase 2 | |
| Recruiting |
NCT04642833 -
Prostate Cancer in Renal Transplants Recipients
|
||
| Not yet recruiting |
NCT05293704 -
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients
|
Phase 4 | |
| Completed |
NCT02555566 -
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study
|
N/A | |
| Completed |
NCT01782586 -
Validation of Gene Expression Markers of Renal Allograft Functional Decline
|
||
| Enrolling by invitation |
NCT02042963 -
KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)
|
N/A | |
| Not yet recruiting |
NCT05702398 -
Pilot Trial of Supplemental Vitamin A and Nicotinamide
|
Early Phase 1 | |
| Active, not recruiting |
NCT05425498 -
The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT01889758 -
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
|
Phase 4 | |
| Terminated |
NCT02268201 -
A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule
|
Phase 4 | |
| Active, not recruiting |
NCT03979365 -
Envarsus XR Compared to Immediate Release Tacrolimus
|
Phase 4 | |
| Recruiting |
NCT04965935 -
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
|
Phase 3 | |
| Recruiting |
NCT04444843 -
Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen
|
Phase 4 | |
| Completed |
NCT02392312 -
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
|
||
| Completed |
NCT02639949 -
Measuring and Improving Medication Adherence in Kidney Transplant Patients
|
N/A |